Cellectis S.A (ALCLS) | Stock Overview & Key Data
Cellectis S.A. | Mid-cap | Healthcare
Cellectis S.A. | Mid-cap | Healthcare
Cellectis S.A Performance Comparison
Stock Range
Today's Range
Low: €2.66
High: €2.85
on September 18, 2025
52 Week Range
Low: €1.01
High: €3.19
on April 7, 2025
on August 4, 2025
All-Time High: €41.95 on November 2, 2015
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Market Cap
€282.5M
EPS
-0.50
P/E Ratio (TTM)
-6.61
Forward P/E
-2.99
P/B Ratio
2.01
PEG Ratio
-2.99
Div. Yield
N/A
ROE
-48.02%
Beta
3.032
Debt to Equity
93.67
Financial Highlights
Profitability
Gross Margin
85.50%
Operating Margin
-52.69%
Profit Margin
-93.00%
Returns and Earnings
Return on Assets (TTM)
-7.43%
Return on Equity (TTM)
-48.02%
EBITDA
€-28.2M
Net Income (TTM)
€-50.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.88
Quarterly Revenue Growth (YoY)
91.40%
Quarterly Earnings Growth (YoY)
76.86%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Cellectis S.A ALCLS | 282.51M Mid-cap | -0.72% | 9.49% | 123.39% | 123.39% | 61.05% | 40.61% | 10.80% | -81.82% |
| Abivax SA ABVX | 5.26B Large-cap | -2.51% | 17.09% | 1,221.36% | 1,109.34% | 860.16% | 587.99% | 724.29% | 282.39% |
| Medincell S.A MEDCL | 656.19M Mid-cap | 8.48% | 20.64% | 28.19% | 46.12% | 20.30% | 30.41% | 287.16% | 201.43% |
| Valneva SE VLA | 649.14M Mid-cap | 9.77% | -15.78% | 75.72% | 31.79% | 84.85% | 68.77% | -24.82% | -38.21% |
| Inventiva S.A IVA | 626.50M Mid-cap | -5.07% | 23.01% | 55.90% | 63.87% | 112.80% | 149.44% | 9.78% | -54.42% |
| BNP Paribas Easy BLUE | 463.10M Mid-cap | 0.25% | 1.01% | 0.57% | 2.70% | -2.32% | -2.44% | 14.78% | 54.29% |
Ownership & Short Interest
Insider Ownership
47.77%
Institutional Ownership
18.60%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
241K
Average 90-Day Volume
287K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ALCLS's 52-week high and low?
- In the last 52 weeks, Cellectis S.A reached a high of €3.19 (on August 4, 2025) and a low of €1.01 (on April 7, 2025).
- What is the market cap and P/E ratio for ALCLS?
- Curious about Cellectis S.A's size and valuation? Its market capitalization stands at 282.51M. When it comes to valuation, the P/E ratio (trailing twelve months) is -6.61, and the forward P/E (looking ahead) is -2.99.
- Does ALCLS pay dividends? If so, what's the yield?
- As for dividends, Cellectis S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Cellectis S.A's main competitors or similar companies to consider before investing?
When looking at Cellectis S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX5.26B Healthcare Biotechnology 587.99% 724.29% Medincell S.A
MEDCL656.19M Healthcare Biotechnology 30.41% 287.16% Valneva SE
VLA649.14M Healthcare Biotechnology 68.77% -24.82% Inventiva S.A
IVA626.50M Healthcare Biotechnology 149.44% 9.78% BNP Paribas Easy
BLUE463.10M Healthcare Biotechnology -2.44% 14.78% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Cellectis S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Cellectis S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -48.02%, the Debt to Equity ratio from the most recent quarter is 93.67, and its Gross Profit Margin stands at 85.50%.
- What is the recent revenue and earnings growth for ALCLS?
- Looking at Cellectis S.A's growth, its revenue over the trailing twelve months (TTM) was €54M. Compared to the same quarter last year (YoY), quarterly revenue grew by 91.40%, and quarterly earnings saw a YoY growth of 76.86%.
- How much of ALCLS stock is held by insiders and institutions?
- Wondering who owns Cellectis S.A stock? Company insiders (like executives and directors) hold about 47.77% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 18.60%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.